In this webinar, Dana will challenge the idea that clinical neuropsychologists are primarily assessors of cognition. She will argue that skills in delivery of interventions and rehabilitation are equally essential, with the potential to add substantial value and impact to our role across a wide range of clinical settings. Dana will outline considerations and recommendations to help guide the selection, effective delivery, and implementation of evidence-based neuropsychological interventions for adults with brain injury and illness. She will provide an overview of the roles neuropsychologists can play in delivering a range of cognitive, psychological and behavioural intervention types, from brief and occasional to extended and regular. Dana will present an overview of what is known about the clinical competencies required for intervention delivery, and methods for sustainable implementation of interventions across clinical settings.
Across all areas of medicine and research, biomarkers are proving to provide great value in diagnosis, prognosis, and treatment of injury or disease. Major progress has been achieved toward advancing blood and imaging biomarkers for TBI and concussion. This session will review emerging evidence from large-scale studies of TBI biomarkers in civilians, athletes and military service members. Pathways for clinical translation and implementation will be discussed. Traumatic Brain Injury (TBI) continues to be one of the leading causes of death and disability in the pediatric population. Current prediction models explain only about 35% of variance in outcomes. At the individual patient level, this unexplained heterogeneity in outcomes prevents accurate prognostication and precision medicine approaches. A simple blood-based biomarker that correlates with the severity and progression of brain injury, similar to troponin in myocardial infarction, would enable appropriate triage in acute treatment, rehabilitation planning, and clinical trial stratification. Yet, few studies have specifically examined blood biomarkers in pediatric TBI. This session will review the current state of biomarker research within pediatric TBI as well as discuss several novel blood biomarkers that have shown promise in the recent years.
This episode is a wide ranging discussion of Parkinson’s disease, with Dr. Sara Schaefer. The conversation begins with basic facts, features, and concepts, and then moves into more complex topics, while covering many critical factors for neuropsychologists to consider. It includes a focus on diagnosis/symptoms, epidemiology, core neuropathology, neurodiagnostic approaches, risk factors (e.g., REM behavior disorder), nonmotor features (e.g., autonomic, neuropsychiatric, cognitive), subtypes, and treatment approaches.
This episode is a conversation with Dr. Maureen Schmitter-Edgecombe about ecological validity, with a focus on methods for capitalizing on digital technologies to maximize ecological validity in neuropsychology. We cover definitions, methods for assessing ecological validity, naturalistic assessment, smart homes, sensors, privacy and security, and a digital memory notebook.
In this episode, we talk with Dr. Jennifer Reesman about neuropsychological evaluations of children from the D/deaf and hard of hearing (DHH) community. We discuss DHH culture, language deprivation syndrome, medical etiologies of hearing loss, sign language and cued speech, cochlear implants, and various considerations for neuropsychological evaluations in children from the DHH community.
In this episode, we discuss polypharmacy and deprescribing with two geriatricians. We cover definitions of polypharmacy, inappropriate polypharmacy, deprescribing as an intervention, specific drug classes with potential for cognitive side effects in older adults, and a neuropsychologist’s role in clinical care related to polypharmacy.
We discuss intellectual disability (ID) with Jennifer Huffman, Ph.D., ABPP-CN, a board certified pediatric neuropsychologist. We discuss diagnosis of ID, including strengths and weaknesses of different test batteries, as well as the importance of adaptive functioning. We also cover etiology (e.g., genetic syndromes), cultural considerations, interventions, and much more.
This episode is a discussion of behavioral variant frontotemporal dementia (bvFTD). We first talk about overlap and differences between the various FTD spectrum conditions. Next, we cover the following topics specific to bvFTD: neuropathology, genetics, and neuroimaging, phenocopy syndrome, the classic clinical and behavioral syndrome, cognitive profile, and treatment options.
Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, with effects on academic and occupational performance, social relationships, and other aspects of functioning. Neuropsychologists frequently work with both children and adults with ADHD, and understanding the relevant scientific literature is an important part of training and continuing education in our field. In this episode, John and Ryan talk to Dr. Robb Mapou about ADHD, including conversations on developmental course, co-occurring symptoms, assessment, diagnosis, and treatment, among other topics.